Pfizer invests in allogeneic CAR-T therapy companyJuly 06, 2023 - Pfizer purchased 4.6 million shares of Caribou common stock at $5.33 per share in a deal that added up to $25 million and closed June 30.
"Durability is a widespread issue for allogeneic CAR-T developers. In an attempt to tackle CAR-T cell exhaustion and maintain high anti-tumor activity for a longer time, Caribou had removed the PD-1 receptors from its anti-CD19 candidate CB-010. However, last year’s results raise questions about the impact of the work to boost durability.
The relapses overshadowed other, more encouraging aspects of the data, like the 100% complete response rate at the starting dose of 40 million CAR-T cells and no high-grade safety events. "
https://www.fiercebiotech.com/biotech/pfizer-pours-25m-equity-investment-caribous-cell-therapies
[ Dr. Richard Vile of the Mayo Clinic has demonstrated that CAR-T therapy + pelareorep followed by a pelareorep "boost" resulted in CAR=T durability that was determined a "cure" in the animal model ]